Latest News

Oryzon completes funding

Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.
Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.


by Uta Mommert

Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

The financing round has been subscribed by several Spanish commercial banks in the form of long term loans at the current interest rates in the Spanish bank market. “These funds complement the capital increase that the company made upon its listing on the Spanish Market, and are a key component to our strategic Financial Plan,” said Enric Rello, CFO of Oryzon. “These funds will be important to further advance our clinical programmes in Alzheimer’s disease and in other devastating diseases.”

Oryzon Genomics has currently two programmes in clinical stage with different LSD1 inhibitors in cancer and neurodegeneration. Recently, the biopharmaceutical company started a Phase I trial of its oral LSD1-MAOB dual inhibitor ORY-2001. With a successful study outcome, ORY-2001 is expected to proceed to a Phase II study in Alzheimer’s disease patients in early 2017.

© european-biotechnology-news.com/um

4BIO Ventures launches US$50m fund

The London-headquartered Venture Captial specialist is targeting US$150m for the final close by the second half of 2020. The 4Bio Ventures II fund...

Swiss researchers report on metastasis switch

The research team headed by Jörg Standfuss deciphered the structure of the CCR7 receptor that plays a crucial role in the migration of cancer cells....

Rottapharm Biotech: POC in osteoarthritis pain

Results of the proof-of-concept trial suggest the selective imidazoline-2 (I2) receptor agonist CR4056 could be an alternative to the...

AM-Pharma raises €116m for Phase III

In a Phase II trial, the recombinant human Alkaline Phosphatase (recAP) showed promise, even though it missed its primary endpoint. After a buyout...

Cell transdifferentiation specialist Mogrify Ltd raises US$16m

The company has developed a unique scalable technology for direct cellular transdifferentiation, based on the FANTOM5 dataset of human regulatory...

Spanish sector attracting more and more investment

According to Spain's biotech association, the investor day attracted 60 investors from nine countries and provided more than 500 partnering...

Pro-apoptotic protein blocks autoimmunity

John Rizk discovered that the SMAC protein (Second mitochondria-derived activator of caspase) besides triggering cancer cell apoptosis have a second...